#United States #Dividend #Indianapolis #Eli Lilly #NYSE:LLY

Eli Lilly Declares $1.50 Dividend for Q2 2025

On May 5, 2025, Eli Lilly and Company (NYSE: LLY) announced a notable dividend for its shareholders. The company’s Board of Directors has declared a dividend of $1.50 per share, which is set to be distributed for the second quarter of 2025. This dividend payment is a testament to Lilly's consistent performance and its commitment to providing value to its investors.

Details of the Dividend Declaration

The dividend will be distributed on June 10, 2025, to shareholders who are on record as of the close of business on May 16, 2025. This timely announcement aligns with Eli Lilly's historical practice of rewarding shareholders as the company continues to thrive within the competitive pharmaceutical industry.

Eli Lilly's Legacy and Commitment to Innovation

Founded nearly 150 years ago, Eli Lilly has been at the forefront of medical innovation, focusing on turning scientific discoveries into healing solutions. The corporation has pioneered various life-changing medications that aid millions globally, addressing critical health challenges like diabetes, obesity, Alzheimer's disease, and certain types of cancer.

The firm’s extensive research has allowed them to harness advancements in biotechnology, chemistry, and genetics to bring forth new treatments that not only improve patient outcomes but also redefine the management of various chronic conditions.

Eli Lilly is dedicated to ensuring these innovations are accessible and affordable for patients worldwide. This includes a robust pipeline of clinical trials aimed at reflecting the diverse population they serve, ensuring that every individual has the opportunity to benefit from their therapies.

Forward-Looking Statements

The announcement of this dividend, however, comes with certain caveats. Eli Lilly highlighted that the details shared in this release encompass forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements reflect the company's current beliefs and expectations concerning various factors. However, the pharmaceutical landscape is filled with uncertainties, and results may vary significantly from these predictions.

Investors are encouraged to review Lilly's SEC filings, specifically Forms 10-K and 10-Q, for a detailed understanding of the risks involved with their investment. Such transparency reflects Lilly's commitment to its shareholders and the broader investment community.

Conclusion

Eli Lilly's declaration for a $1.50 dividend showcases its strong financial health and dedication to shareholder value, even as they navigate the challenges posed by the global pharmaceutical industry. For those interested in following the company’s journey and its advancements in medical science, further details can be found on their official website, Lilly.com, as well as through their social media channels.

Eli Lilly continues to strive for a mission of making life better for patients and their families—a testament to their enduring influence in medicine and patient care. As the company looks ahead, stakeholders will remain optimistic about their upcoming ventures and continued commitment to transformative health solutions.